Cost-effectiveness analysis of ainuovirine versus efavirenz in HIV population initiating first-line combination antiretroviral therapy

被引：0
|
作者：
Yang, Chenlu [1 ]
Mi, Yuanqi [2 ]
Zeng, Yuhong [3 ]
Cheng, Feng [4 ]
Zheng, Yufang [5 ]
Zhang, Chunyun [5 ]
Qin, Hong [5 ]
Zeng, Huatang [6 ]
Zhou, Mengge
机构：
[1] Chinese Acad Med Sci, Dept Epidemiol & Biostat, Inst Basic Med Sci, Beijing, Peoples R China
[2] Peking Union Med Coll, Sch Basic Med, Beijing, Peoples R China
[3] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[4] Third Mil Med Univ, Dept Epidemiol, Coll Prevent Med, Army Med Univ, Chongqing, Peoples R China
[5] Jiangsu Aidea Pharmaceut Co Ltd, Clin Res & Dev, Yangzhou, Jiangsu, Peoples R China
[6] Shenzhen Hlth Dev Res & Data Management Ctr, Shenzhen, Peoples R China
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2024年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P267
引用
收藏
页码：237 / 237
页数：1
相关论文
共 50 条
  • [21] Single versus multiple tablet regimens for first-line antiretroviral treatment of HIV: A real-world cost-effectiveness analysis using a patient cohort in Brazil
    de Oliveira Costa, J.
    Botha, W.
    Braga Ceccato, M. D. G.
    Pearson, S.
    Goodall, S.
    de Assis Acurcio, F.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 162 - 162
  • [22] Has the time come to abandon efavirenz for first-line antiretroviral therapy?
    Raffi, Francois
    Pozniak, Anton L.
    Wainberg, Mark A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) : 1742 - 1747
  • [23] Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy
    Dorward, Jienchi
    Sookrajh, Yukteshwar
    Lessells, Richard
    Bulo, Elliot
    Bodley, Nicola
    Singh, Lavanya
    Moodley, Pravikrishnen
    Samsunder, Natasha
    Drain, Paul K.
    Hayward, Gail
    Butler, Christopher C.
    Garrett, Nigel
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 95 (05) : e8 - e11
  • [24] Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma
    Liu, Shixian
    Dou, Lei
    Wang, Kaixuan
    Shi, Zhao
    Wang, Ruixue
    Zhu, Xiaohong
    Song, Zehua
    Li, Shunping
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore
    Paton, Nicholas I.
    Chapman, Chere A. T.
    Sangeetha, S.
    Mandalia, Sundhiya
    Bellamy, Richard
    Beck, Eduard J.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (10) : 699 - 705
  • [26] Cost-Effectiveness of Tenofovir Instead of Zidovudine for Use in First-Line Antiretroviral Therapy in Settings without Virological Monitoring
    von Wyl, Viktor
    Cambiano, Valentina
    Jordan, Michael R.
    Bertagnolio, Silvia
    Miners, Alec
    Pillay, Deenan
    Lundgren, Jens
    Phillips, Andrew N.
    PLOS ONE, 2012, 7 (08):
  • [27] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [28] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [29] Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial
    Long, Lawrence C.
    Maskew, Mhairi
    Brennan, Alana T.
    Mongwenyana, Constance
    Nyoni, Cynthia
    Malete, Given
    Sanne, Ian
    Fox, Matthew P.
    Rosen, Sydney
    AIDS, 2017, 31 (11) : 1611 - 1619
  • [30] COST-EFFECTIVENESS ANALYSIS OF FILGOTINIB VERSUS TOFACITINIB AS FIRST-LINE TREATMENTS FOR RHEUMATOID ARTHRITIS IN GREECE
    Nomikos, N.
    Naoum, P.
    Athanasakis, K.
    Kyriopoulos, I
    VALUE IN HEALTH, 2024, 27 (12) : S80 - S80
12345